A retrospective study of ulinastatin for the treatment of severe sepsis. Issue 49 (4th December 2020)

• Record Type: Journal Article
• Authors: Meng, Chao; Qian, Yi; Zhang, Wen-hao; Liu, Ying; Song, Xiao-chun; Liu, Han; Wang, Xiang
• Other Names: Haque. Nazmul section editor.
• Is Part Of: Medicine. Volume 99:Issue 49(2020)
• Publication Date: 2020-12-04
• Subjects: adverse events -- efficacy -- severe sepsis -- ulinastatin; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000023361
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: This retrospective study aimed to investigate the efficacy and safety of existing approach of ulinastatin for the treatment of severe sepsis (SS). A total of 130 eligible patients with SS were included in this study. We divided them into an intervention group (n = 65) and a control group (n = 65). Patients in both groups received conventional therapy. In addition, patients in the intervention group received ulinastatin for 7 days. Outcomes were measured by Acute Physiology and Chronic Health Evaluation II (APACHE II), Multiple Organ Failure (MOF), Glasgow Coma Scale (GCS), CD3 +, CD4 +, CD8 +, CD4 + /CD8 +, and adverse events. We assessed all outcomes before and after treatment. After treatment, patients in the intervention group showed better improvement in APACHE II ( P < .01), MOF ( P < .01), GCS ( P < .01), CD3 + ( P = .03), CD4 + ( P = .03), and CD4 + /CD8 + ( P < .01), than those of patients in the control group. There are similar safety profiles between both groups. This study suggests that ulinastatin may be beneficial for SS. Future studies are still needed to warrant the results of this study.